Final Impressions from ISPOR EU 2024
Transcript:
Christopher Graham, MS,
Head Health Economics, RTI Health Solutions
Really excited to be here in Barcelona. The inclusion of caregiver qualities or carer qualities, in health economic modelings is really important lately. I saw a great session about extending that to include bereavement qualities. I'm really excited to see where the research goes from here and to contribute to it.
Sarah Sauchelli Toran, PhD
Senior Researcher, Patient-Centered Outcomes Assessment
What's been fabulous about ISPOR Conference this year has been all the talk about AI. We've seen some, developments since ISPOR last year. There are nonetheless a lot of remaining concerns about safe AI use and how regulatory agencies, and FDA as well, accept work produced by AI. What would be great to see in the future is a lot more cases, examples of successful use of AI and ideally, cross-sector collaborations to make these stories be available, with some practical guidance from regulatory bodies in HTAs to contribute as well.
Clem Hindley, PhD
Senior Scientific Strategy Lead
I've actually spent my career supporting medical affairs, so this has been my first experience at ISPOR, and it's been a fantastic time to immerse myself in the data and the real key topics of interest, such as JCA. What's been great has also been having conversations with people around how we can really make sure that these data are used strategically and communicated effectively because they’ve got impact beyond your traditional payer and regulator audiences for other decision makers, such as HCPs and patients. So, excited to see how we can use these going forward.
Jacco Keja, PhD
Senior Vice President, Strategic Consulting and Growth
One of the impressions I have, looking at a lot of booths, but also presentations, that people get more realistic about what machine learning artificial intelligence can bring us. Not over promising, not under promising, getting more realistic. That's one take-home message for me from this ISPOR. The second one is that, and that's a bigger concern, people are still confused about what joint clinical assessment is going to bring. The matter of the fact is that people are very focused on now doing it right, making it in time, of how it is going to be used in detail, and whether or not that framework is appropriate.
For example for rare disease is still under heavy debate, which is a little bit surprising with two months to go before the JCA is in effect. The final impression - HEOR is still in search of their destiny. A lot of people are being real organized in the pharmaceutical industry. A lot of companies are bringing HEOR into Medical Affairs, and Medical Affairs doesn't know really what HEOR can bring to them and vice versa.
Whereas, I think the basic philosophy to bring them under one umbrella is a good one, because what is important is you take into account social diversity that we take into account implementation science. HEOR is more than just bringing something to NICE or supporting an AMNOG dossier.